A New Hope for Glioblastoma: How a European Grant Fuels a Precision Attack on Brain Cancer

UPPSALA, Sweden – February 17, 2026 – In the relentless fight against one of the most formidable human cancers, a significant new investment is igniting a beacon of hope. Swedish precision medicine firm Beactica Therapeutics, in partnership with top researchers at Belgium's KU Leuven, has secured a highly competitive EUR 2.5 million grant from the European Innovation Council (EIC). The funding is set to accelerate the development of BEA-17, a novel, first-in-class drug candidate aimed at glioblastoma, the most common and aggressive form of brain cancer.

This prestigious award will fuel the GLIOBREAK project, a 30-month initiative designed to propel BEA-17 from a validated laboratory concept to the brink of human clinical trials. For the tens of thousands of patients diagnosed with glioblastoma each year, who face a median survival of just 15 months, the advancement of such a promising new therapy represents a critical step forward in a field that has seen limited progress for decades.

Confronting a Formidable Foe: The Glioblastoma Challenge

Glioblastoma (GBM) is notoriously difficult to treat. Its aggressive nature stems from a combination of factors that have thwarted conventional therapeutic strategies. The current standard of care—a grueling regimen of surgery, radiation, and chemotherapy with the drug temozolomide—can slow the disease but rarely provides a cure. With a five-year survival rate lingering at a grim 5%, the need for transformative innovation is profound.

One of the primary obstacles is the brain's own defense mechanism: the blood-brain barrier (BBB). This protective layer of cells effectively shields the brain from toxins and pathogens but also blocks the vast majority of cancer drugs from reaching their target. Furthermore, glioblastoma tumors are masters of disguise and defense. They are considered immunologically "cold," meaning they have created a highly immunosuppressive tumor microenvironment (TME) that cloaks them from the body's immune system and renders most modern immunotherapies ineffective.

The tumor's profound cellular diversity, or heterogeneity, adds another layer of complexity. Even within a single tumor, different cells can have different genetic makeups, allowing the cancer to quickly develop resistance to treatments. This resilience has left clinicians with a limited arsenal and patients with few viable options, making the search for drugs that can overcome these barriers a global health priority.

Rewriting the Rules: The Science of BEA-17

BEA-17 represents a paradigm shift from traditional cancer therapies. It is not a conventional inhibitor but a targeted protein degrader, a cutting-edge approach developed using Beactica’s proprietary Eclipsor™ platform. Instead of merely blocking the function of a problematic protein, BEA-17 hijacks the cell's natural disposal system—the ubiquitin-proteasome system—to completely eliminate its target: an epigenetic protein complex known as LSD1–CoREST.

The LSD1–CoREST complex acts as a cellular "switch," regulating gene expression. In many cancers, including glioblastoma, it is overactive and helps the tumor grow and evade the immune system. By degrading this complex, BEA-17 triggers a cascade of beneficial anti-cancer effects, a strategy that falls under the emerging field of immuno-epigenetics.

This mechanism aims to turn the "cold" glioblastoma tumor "hot." By removing LSD1–CoREST, BEA-17 forces cancer cells to display more antigens (markers that the immune system can recognize), induces a state of "viral mimicry" that tricks the immune system into attacking, and reprograms suppressive immune cells within the tumor to become active fighters. Critically, preclinical studies have shown that BEA-17 has two essential properties for a brain cancer drug: it is orally available and demonstrates good penetration of the blood-brain barrier.

A Strategic Alliance Forged by European Innovation

The GLIOBREAK project is more than just a drug development program; it is a powerful synergy of industry innovation and academic excellence. Beactica brings its specialized Eclipsor™ platform and expertise in targeted protein degradation, while KU Leuven contributes world-leading research in glioblastoma biology. The collaboration involves three KU Leuven teams led by Prof. Frederik De Smet, Prof. An Coosemans, and Prof. Thierry Voet, who bring deep expertise in translating patient data, using advanced (spatial) single-cell technologies, and validating therapies in state-of-the-art preclinical models.

Securing the EIC Transition grant is a monumental validation of this collaborative approach. The program is designed to bridge the crucial gap between scientific discovery and market-ready products. The fact that the GLIOBREAK proposal was one of only 40 selected from a pool of 611 submissions in one of the most competitive calls ever underscores the exceptional promise of the science. The non-dilutive funding allows Beactica to aggressively pursue development without impacting shareholder equity, focusing all resources on the scientific mission.

"We are delighted to receive this prestigious EIC Transition award together with our eminent collaborators at KU Leuven," said Dr. Per Källblad, CEO of Beactica. "It is a significant validation of our immuno-epigenetic approach to glioblastoma, a disease with devastating outcomes where patients urgently need new therapeutic options. This funding enables us to complete our IND-enabling studies and move toward first-in-human trials, bringing this first-in-class LSD1-CoREST degrader closer to patients."

Paving the Path to the Clinic

The EUR 2.5 million grant will be deployed over 30 months to achieve a singular, vital goal: making BEA-17 ready for its first clinical trial in humans. This involves conducting a rigorous series of IND-enabling studies—the comprehensive preclinical safety, toxicology, and manufacturing tests required by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The project builds on foundational work from a prior EU-financed project, GLIOMATCH, which helped develop the biomarker-driven diagnostic that will be integrated with the new therapy.

Successful completion of this phase will culminate in a regulatory application to begin a Phase 1 clinical trial. This step from preclinical research to human testing is one of the most significant milestones in a drug's journey. The FDA has already granted BEA-17 an Orphan Drug Designation for the treatment of glioblastoma, a status given to promising therapies for rare diseases that provides incentives to support their development.

By combining a first-in-class therapeutic with a companion diagnostic developed at KU Leuven, the GLIOBREAK project embodies the future of precision medicine. This integrated approach aims not only to treat the disease more effectively but also to identify the patients most likely to benefit, maximizing the potential for positive outcomes. For those facing a glioblastoma diagnosis, this convergence of cutting-edge science, strategic collaboration, and substantial European support marks a crucial and hopeful advance in the quest for a longer, better life.